Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma filed its February 2026 investor presentation covering FY25 results and Q3 FY26 performance. FY25 sales stood at Rs 520,412 mn, up 9% YoY, with adjusted net profit of Rs 119,844 mn, up 19% YoY. Q3 FY26 showed strong momentum: revenue grew 15.1% YoY to Rs 154,691 mn, and EBITDA margin expanded to 31.9% from 29.3% in Q3 FY25, driven by growth across India (+16.2%), Emerging Markets (+28.3%), and Rest of World (+20.8%). Innovative Medicines now contribute 20% of sales (up from 7.3% in FY18) with key products like Ilumya, Cequa, and the recently acquired Checkpoint Therapeutics' UNLOXCYT. The company is net cash positive with a market cap of US$45 Bn and guides for mid-to-high single digit consolidated revenue growth for FY26.
The presentation underscores strong, broad-based growth and expanding profitability, with EBITDA margins reaching a multi-year high of 31.9% in Q3 FY26. For shareholders, this reflects improving return ratios (ROCE 20.5%, ROE 17.4% in FY25) and a healthy balance sheet, likely to be viewed positively by the market.